Biocartis Group NV
Develops and commercializes an automated molecular diagnostics platform for oncology.
BCART | BR
Overview
Corporate Details
- ISIN(s):
- BE0974281132 (+1 more)
- LEI:
- 549300J4HOJL5KG8HY54
- Country:
- Belgium
- Address:
- GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
- Website:
- https://www.biocartis.com/en
- Sector:
- Manufacturing
Description
Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-04-11 10:07 |
AGM 2017 - Explanatory Note (DUT) (final).pdf
|
Dutch | 222.5 KB | ||
| 2017-04-11 10:07 |
AGM 2017 - Attendance form (ENG) (final).pdf
|
English | 199.8 KB | ||
| 2017-04-11 10:07 |
AGM 2017 - Attendance form (DUT) (final).pdf
|
Dutch | 275.0 KB | ||
| 2017-04-11 10:07 |
PR AGM invitation ENG FINAL.pdf
|
English | 131.7 KB | ||
| 2017-04-11 10:07 |
PR AGM invitation NL FINAL.pdf
|
Dutch | 133.3 KB | ||
| 2017-03-30 07:56 |
Biocartis Annual Report 2016_ENG_FINAL_web_unsigned.pdf
|
English | 8.2 MB | ||
| 2017-03-30 07:56 |
Biocartis Annual Report 2016_NL_FINAL_web_unsigned.pdf
|
Dutch | 8.6 MB | ||
| 2017-03-02 07:32 |
170301 Press Release 2016FY Results ENG-FINAL.pdf
|
English | 585.1 KB | ||
| 2017-03-02 07:32 |
170301 Press Release 2016FY Results NL-FINAL.pdf
|
Dutch | 524.4 KB | ||
| 2017-03-02 07:31 |
BIOCARTIS ANNOUNCES 2016 RESULTS, 2017 OUTLOOK AND CHANGE IN CEO POSITION
|
English | 585.1 KB | ||
| 2017-03-02 07:31 |
BIOCARTIS KONDIGT 2016 RESULTATEN, 2017 VOORUITZICHTEN EN VERANDERING IN CEO PO…
|
Dutch | 524.4 KB | ||
| 2016-12-22 09:11 |
Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe
|
English | 138.8 KB | ||
| 2016-12-22 09:11 |
Biocartis en Amgen ondertekenen samenwerking voor RAS-biomerker testing in Eur…
|
Dutch | 140.8 KB | ||
| 2016-12-14 08:25 |
Transparency notification JJDC Inc.pdf
|
Dutch | 167.2 KB | ||
| 2016-12-14 08:25 |
PR Transp notif JJDC ENG FINAL.pdf
|
English | 288.6 KB |
Automate Your Workflow. Get a real-time feed of all Biocartis Group NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biocartis Group NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biocartis Group NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-04-29 | Devogelaere Benoit | Executive member | Buy | 15,000 | N/A |
| 2021-04-28 | Marcofin BV | Executive member | Buy | 30,000 | N/A |
| 2021-04-27 | Herman Verrelst | Board | Buy | 60,000 | N/A |
| 2020-11-13 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2020-05-06 | Herman Verrelst | Board | Buy | 50,000 | 249,625.00 EUR |
| 2020-05-06 | Herman Verrelst | Board | Buy | 300,000 | N/A |
| 2020-05-04 | Herman Verrelst | Board | Buy | 46,803 | 231,656.00 EUR |
| 2020-05-04 | Herman Verrelst | Board | Buy | 3,197 | 15,315.00 EUR |
| 2019-12-18 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2019-12-16 | Welten Ewoud | Executive member | Buy | 10,000 | N/A |
Peer Companies
